Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068585 | 0.90 | PTGS1 (0.39) | PLA2G2AARALDH1A1SMN1; SMN2GLA | |
| SCHEMBL3074091 | 0.87 | KMT2A (0.36) | ARNPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16858285 | 0.73 | NR1H2 (0.37) | ARBRD4NPC1RAB9AKDM4E | |
| SCHEMBL3063211 | 0.73 | KMT2A (0.38) | ARNPC1KDM4ENPSR1 | |
| SCHEMBL3060845 | 0.73 | AR (0.32) | ARALDH1A1SMN1; SMN2NPSR1HPGD | |
| SCHEMBL3063123 | 0.73 | TAAR1 (0.35) | KDM4ESMN1; SMN2HPGD | |
| SCHEMBL3053121 | 0.73 | CCR2 (0.38) | KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL3076554 | 0.69 | KMT2A (0.37) | PLA2G2ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3073957 | 0.68 | HPGD (0.34) | ARALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL3068887 | 0.68 | SMN1; SMN2 (0.40) | NPC1ALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-28 | — | — | US | claimed |
| EP-2220051-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | Syngenta Participations AG (CH) | 2010-08-25 | — | — | EP | claimed |
| WO-2009080314-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-02 | — | — | WO | claimed |
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2220051-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | Syngenta Participations AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009080314-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | C3AR1, CBR3, C1S | PLA2G2A 2168/4885NR1I2 1221/4885CASR 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.